ХРОНИЧЕСКИЙ ВИРУСНЫЙ ГЕПАТИТ И ВОСПАЛИТЕЛЬНЫЕ ЗАБОЛЕВАНИЯ КИШЕЧНИКА
Аннотация
В статье представлены результаты обзора литературы, посвященного изучению проблем сочетанного течения воспалительных заболеваний кишечника (ВЗК), к которым относятся язвенный колит (ЯК) и болезнь Крона (БК), хронических вирусных гепатитов (ХВГ) – хронического гепатита В (ХГВ) и хронического гепатита С (ХГС). Представлена частота встречаемости ХГВ и ХГС при ВЗК в разных странах, которая составляет от 1 до 9%. Описывается клиническое течение этих сочетанных заболеваний, возможности реактивации вируса гепатита В (HBV) и вируса гепатита С (HCV) на фоне иммуносупрессивной терапии. Представлены рекомендации по особенностям обследования и ведения пациентов с сочетанной патологией ВЗК и ХВГ. Сочетанная патология ВЗК и ХВГ представляет собой значительную проблему здравоохранения во всем мире, которая требует дальнейшего масштабного изучения. Использование иммуносупрессивной терапии при ВЗК может сопровождаться активацией HBV и HCV инфекции, поэтому ведение таких пациентов должно быть индивидуальным.
Литература
Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D’Haens G, D’Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J. Crohns Colitis. 2012;6(10):991-1030. https://doi.org/10.1016/j.crohns.2012.09.002.
Jairath V, Feagan BG. Global burden of inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2020;5(1):2-3. https://doi.org/10.1016/S2468-1253(19)30358-9.
Bibbò S, Ianiro G, Dore MP, Simonelli C, Newton EE, Cammarota G. Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease. Mediators Inflamm. 2018;2018:9321643. https://doi.org/10.1155/2018/9321643.
Biancone L, Del Vecchio Blanco G, Pallone F, Castiglione F, Bresci G, Sturniolo G; Italian Group for the Study of the Colon and Rectum. Immunomodulatory drugs in Crohn’s disease patients with hepatitis B or C virus infection. Gastroenterology. 2002;122(2):593-4. https://doi.org/10.1053/gast.2002.31602.
Biancone L, Pavia M, Del Vecchio Blanco G, D’Incà R, Castiglione F, De Nigris F, Doldo P, Cosco F, Vavassori P, Bresci GP, Arrigoni A, Cadau G, Monteleone I, Rispo A, Fries W, Mallardi B, Sturniolo GC, Pallone F. Hepatitis B and C virus infection in Crohn’s disease. Inflamm Bowel Dis. 2001;7(4):287-94. https://doi.org/10.1097/00054725-200111000-00002.
Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn’s disease. Inflamm Bowel Dis. 2007;13(11):1453-4. https://doi.org/10.1002/ibd.20216.
Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis. 2007;13(4):508-9. https://doi.org/10.1002/ibd.20035.
Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn’s disease: need for HBV-screening? World J Gastroenterol. 2006;12(6):974-6. https://doi.org/10.3748/wjg.v12.i6.974.
Zeitz J, Mullhaupt B, Fruehauf H, Rogler G, Vavricka SR. Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone. Hepatology. 2009;50(2):653-4. https://doi.org/10.1002/hep.23035.
Basnayake SK, Easterbrook PJ. Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature. J Viral Hepat. 2016;23(7):545-559. https://doi.org/10.1111/jvh.12519.
Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis. 2010;16(6):925-32. https://doi.org/10.1002/ibd.21284.
Chevaux JB, Nani A, Oussalah A, Venard V, Bensenane M, Belle A, Gueant JL, Bigard MA, Bronowicki JP, PeyrinBiroulet L. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis. 2010;16(6):916-924. https://doi.org/10.1016/j.gcb.2009.03.021.
Loras C, Saro C, Gonzalez-Huix F, Mínguez M, Merino O, Gisbert JP, Barrio J, Bernal A, Gutiérrez A, Piqueras M, Calvet X, Andreu M, Abad A, Ginard D, Bujanda L, Panés J, Torres M, Fernández-Bañares F, Viver JM, Esteve M. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: A nationwide multicenter study. Am J Gastroenterol. 2009;104(1):57-63. https://doi.org/10.1038/ajg.2008.4.
Morisco F, Castiglione F, Rispo A, Stroffolini T, Sansone S, Vitale R, Guarino M, Biancone L, Caruso A, D’Inca R, Marmo R, Orlando A, Riegler G, Donnarumma L, Camera S, Zorzi F, Renna S, Bove V, Tontini G, Vecchi M, Caporaso N. Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection. J Viral Hepat. 2013;20(3):200-208. https://doi.org/10.1111/j.1365-2893.2012.01643.x.
Papa A, Felice C, Marzo M, Andrisani G, Armuzzi A, Covino M, Mocci G, Pugliese D, De Vitis I, Gasbarrini A, Rapaccini GL, Guidi L. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-alpha agents. J Crohns Colitis. 2013(2);7:113-119. https://doi.org/10.1016/j.crohns.2012.03.001.
Sansone S, Guarino M, Castiglione F, Rispo A, Auriemma F, Loperto I, Rea M, Caporaso N, Morisco F. Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. World J Gastroenterol. 2014;20(13):3516-3524. https://doi.org/10.3748/wjg.v20.i13.3516.
Losurdo G, Iannone A, Contaldo A, Barone M, Ierardi E, Di Leo A, Principi M. Chronic Viral Hepatitis in a Cohort of Inflammatory Bowel Disease Patients from Southern Italy: A Case-Control Study. Pathogens. 2020;9(11):870. https://doi.org/10.3390/pathogens9110870.
World Health Organization. Hepatitis C [Internet]. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/.
Badia E, Barrio J, Fernández-Salazar L, Fuentes A, Hontoria G, Sicilia B. Prevalence of viral hepatitis in patients with IBD: A multi-centre and population-based study. J. Crohn’s Colitis. 2018;12(Suppl 1):S534-S534. https://doi.org/10.1093/ecco-jcc/jjx180.954.
He Y, Xu P, Chen Y, Yang R, Chen B, Zeng Z, Chen M. Prevalence and influences of hepatitis B virus infection on inflammatory bowel disease: a retrospective study in southern China. Int J Clin Exp Med. 2015;8(5):8078-85.
Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees CW, Macmahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel JF. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn Colitis. 2014;8(6):443-468. https://doi.org/10.1016/j.crohns.2013.12.013.
Belle A, Baumann C, Bigard MA, Zallot C, Gizard E, Guéant JL, Bronowicki JP, Peyrin-Biroulet L. Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 2015;27(8):877-81. https://doi.org/10.1097/MEG.0000000000000370.
Jiang HY, Wang SY, Deng M, Li YC, Ling ZX, Shao L, Ruan B. Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: A systematic review and meta-analysis. Vaccine. 2017;35(20):2633-2641. https://doi.org/10.1016/j.vaccine.2017.03.080.
Cossio-Gil Y, Martínez-Gómez X, Campins-Martí M, Rodrigo-Pendás JÁ, Borruel-Sainz N, Rodríguez-Frías F, Casellas-Jordà F. Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination. J Gastroenterol Hepatol. 2015;30(1):92-8. https://doi.org/10.1111/jgh.12712.
Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P, Langner C, Limdi JK, Pellino G, Zagórowicz E, Raine T, Harbord M, Rieder F. Third European Evidencebased Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extraintestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11(6):649-670. https://doi.org/10.1093/ecco-jcc/jjx008.
Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology. 2011;50(9):1700-11. https://doi.org/10.1093/rheumatology/ker190.
Scherzer TM, Staufer K, Novacek G, Steindl-Munda P, Schumacher S, Hofer H, Ferenci P, Vogelsang H. Efficacy and safety of antiviral therapy in patients with Crohn’s disease and chronic hepatitis C. Aliment Pharmacol Ther. 2008;28(6):742-8. https://doi.org/10.1111/j.1365-2036.2008.03779.x.
Tilg H, Vogelsang H, Ludwiczek O, Lochs H, Kaser A, Colombel JF, Ulmer H, Rutgeerts P, Krüger S, Cortot A, D’Haens G, Harrer M, Gasche C, Wrba F, Kuhn I, Reinisch W. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut. 2003;52(12):1728-33. https://doi.org/10.1136/gut.52.12.1728.
Koff RS. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2014;39(5):478-87. https://doi.org/10.1111/apt.12601.
Imperatore N, Castiglione F, Rispo A, Sessa A, Caporaso N, Morisco F. Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases. Front Pharmacol. 2017;8:867. https://doi.org/10.3389/fphar.2017.00867.
Yenilmez E, Cetinkaya RA. Overuse of prophylaxis in HBsAg and/or anti-HBc positive patients after increasing awareness to prevent reactivation in patients receiving immunosuppressive therapies: How rational are our prophylaxis decisions according to the literature? Infez Med. 2019;27(3):299-307.
del Valle García-Sánchez M, Gómez-Camacho F, PoyatoGonzález A, Iglesias-Flores EM, de Dios-Vega JF, SanchoZapatero R. Infliximab therapy in a patient with Crohn’s disease and chronic hepatitis B virus infection. Inflamm Bowel Dis. 2004;10(5):701-2. https://doi.org/10.1097/00054725-200409000-00035.
Esteve M, Loras C, González-Huix F. Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn’s disease patient. Inflamm Bowel Dis. 2007;13(11):1450-1. https://doi.org/10.1002/ibd.20202.
Loras C, Gisbert JP, Mínguez M, Merino O, Bujanda L, Saro C, Domenech E, Barrio J, Andreu M, Ordás I, Vida L, Bastida G, González-Huix F, Piqueras M, Ginard D, Calvet X, Gutiérrez A, Abad A, Torres M, Panés J, Chaparro M, Pascual I, Rodriguez-Carballeira M, Fernández-Bañares F, Viver JM, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut. 2010;59(10):1340-6. https://doi.org/10.1136/gut.2010.208413.
Ojiro K, Naganuma M, Ebinuma H, Kunimoto H, Tada S, Ogata H, Iwao Y, Saito H, Hibi T. Reactivation of hepatitis B in a patient with Crohn’s disease treated using infliximab. J Gastroenterol. 2008;43(5):397-401. https://doi.org/10.1007/s00535-008-2165-x.
Ueno Y, Tanaka S, Shimamoto M, Miyanaka Y, Hiyama T, Ito M, Kitadai Y, Yoshihara M, Sumii M, Chayama K. Infliximab therapy for Crohn’s disease in a patient with chronic hepatitis B. Dig Dis Sci. 2005;50(1):163-6. https://doi.org/10.1007/s10620-005-1295-8.
Samonakis DN, Triantos CK, Thalheimer U, Quaglia A, Leandro G, Teixeira R, Papatheodoridis GV, Sabin CA, Rolando N, Davies S, Dhillon AP, Griffiths P, Emery V, Patch DW, Davidson BR, Rolles K, Burroughs AK. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl. 2005;11(4):386-95. https://doi.org/10.1002/lt.20344.
Zekry A, Gleeson M, Guney S, McCaughan GW. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl. 2004;10(1):52-7. https://doi.org/10.1002/lt.20000.
Schiavon LL, Carvalho-Filho RJ, Narciso-Schiavon JL, Barbosa DV, Lanzoni VP, Ferraz ML, Silva AE. Impact of cyclosporine-based immunosuppressive therapy on liver histology of hepatitis C virus-infected renal transplant patients. Hepatology. 2008;48(1):348-9. https://doi.org/10.1002/hep.22331.
Campbell S, Ghosh S. Infliximab therapy for Crohn’s disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol. 2001;13(2):191-2. https://doi.org/10.1097/00042737-200102000-00016.
Huang ML, Xu XT, Shen J, Qiao YQ, Dai ZH, Ran ZH. Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China: a retrospective study. J Crohns Colitis. 2014;8(4):282-7. https://doi.org/10.1016/j.crohns.2013.08.017.
Nardone A, Anastassopoulou CG, Theeten H, Kriz B, Davidkin I, Thierfelder W, O’Flanagan D, Bruzzone B, Mossong J, Boot HJ, Butur D, Slaciková M, Panait ML, Hellenbrand W, DE Melker H, Sobotová Z, Icardi G, Andrews N, Pebody RG, VAN Damme P, Kafatos G, Miller E, Hatzakis A. A comparison of hepatitis B seroepidemiology in ten European countries. Epidemiol Infect. 2009;137(7):961-9. https://doi.org/10.1017/S0950268808001672.
Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D’Haens G, Domènech E, Eliakim R, Eser A, Frater J, Gassull M, Giladi M, Kaser A, Lémann M, Moreels T, Moschen A, Pollok R, Reinisch W, Schunter M, Stange EF, Tilg H, Van Assche G, Viget N, Vucelic B, Walsh A, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3(2):47-91. https://doi.org/10.1016/j.crohns.2009.02.010.
Volynets GV, Khavkin AI. Sovremennyj vzgljad na immunologicheskie aspekty hronicheskogo gepatita C u detej [A modern view of the immunological aspects of chronic hepatitis C in children]. Infekcionnye bolezni [Infectious diseases]. 2020;18(1):67-76. https://doi.org/10.20953/1729-9225-2020-1-67-76. (Russian).
Turkova A, Volynets GV, Crichton S, Skvortsova TA, Panfilova VN, Rogozina NV, Khavkin AI, Tumanova EL, Indolfi G, Thorne C. Advanced liver disease in Russian children and adolescents with chronic hepatitis C. J Viral Hepat. 2019;26(7):881-892. https://doi.org/10.1111/jvh.13093.
2.png)
